论文部分内容阅读
Bepridil是新的钙拮抗剂。首先由法国制造,并用于治疗心绞痛。目前,在欧美国家已进行了广泛地实验和临床研究,看来是个很有前途的药物。今就有关资料综述如下。药理作用 (一) 作用机制:Bepridil具有传统钙拮抗剂的基本作用机制,即抑制钙离子的跨膜内流,尤其在动作电位期间抑制钙离子经慢通道进入细胞内。这种抑制作用与细胞膜内外的电位差和药物剂量有关。 (二) 对心血管功能的作用:Bepridil与其他钙拮抗剂的化学结构完全不同,但它们对心血管功能却有某些相似的作用(见表)。
Bepridil is a new calcium antagonist. First made in France and used to treat angina. At present, extensive experimental and clinical studies have been conducted in Europe and the United States and appear to be a promising drug. The relevant information is summarized as follows. Pharmacological effects (A) Mechanism of action: Bepridil has the basic mechanism of traditional calcium antagonists, that is, inhibit the transmembrane influx of calcium ions, especially in the action potential inhibition of calcium channels into the cells through the slow channel. This inhibition is related to the potential difference between the inside and outside of the cell membrane and the dose of the drug. (B) the role of cardiovascular function: Bepridil and other calcium antagonists completely different chemical structure, but they have some similar cardiovascular function (see table).